FCAR
FCAR（FcαRI），全稱為高親和力免疫球蛋白E受體I，常見(jiàn)別名包括CD89。該蛋白主要表達(dá)于嗜酸性粒細(xì)胞、肥大細(xì)胞和血小板等細(xì)胞上，其核心功能是介導(dǎo)免疫球蛋白E（IgE）與靶細(xì)胞結(jié)合，引發(fā)I型超敏反應(yīng)及其他免疫應(yīng)答。FCAR通過(guò)與IgE結(jié)合，激活下游信號(hào)分子，如磷脂酰肌醇3-激酶（PI3K）和蛋白激酶C（PKC），進(jìn)而促進(jìn)細(xì)胞脫顆粒、釋放炎癥介質(zhì)和趨化因子，參與過(guò)敏反應(yīng)和抗感染過(guò)程。此外，F(xiàn)CAR還與某些自身免疫性疾病和腫瘤的發(fā)病機(jī)制相關(guān)，例如過(guò)敏性哮喘、過(guò)敏性鼻炎和某些血液系統(tǒng)腫瘤。在藥物研發(fā)領(lǐng)域，針對(duì)FCAR的抑制劑被開(kāi)發(fā)用于治療過(guò)敏性疾病，如抗IgE抗體和FCAR單克隆抗體，以減少I(mǎi)gE介導(dǎo)的過(guò)度炎癥反應(yīng)。目前，相關(guān)藥物已進(jìn)入臨床試驗(yàn)階段，顯示出良好的治療效果和安全性。
熱銷產(chǎn)品
驗(yàn)證數(shù)據(jù)
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA258899(FCAR Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)
The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using CSB-PA258899(FCAR Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: CSB-PA258899(FCAR Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds
FCAR Antibodies
FCAR for Homo sapiens (Human)
| 產(chǎn)品貨號(hào) | 產(chǎn)品名稱 | 種屬反應(yīng)性 | 應(yīng)用類型 |
|---|---|---|---|
| CSB-PA008531GA01HU | FCAR Antibody | Human | ELISA,WB |
| CSB-PA006140 | FCAR Antibody | Human | WB, ELISA |
| CSB-PA258899 | FCAR Antibody | Human,Mouse | ELISA,WB,IHC |
| CSB-PA573035 | FCAR Antibody | Human,Mouse | ELISA,WB,IHC |
FCAR Proteins
FCAR Proteins for Homo sapiens (Human)
| 產(chǎn)品貨號(hào) | 產(chǎn)品名稱 | 來(lái)源 |
|---|---|---|
| CSB-YP008531HU1 CSB-EP008531HU1 CSB-BP008531HU1 CSB-MP008531HU1 CSB-EP008531HU1-B |
Recombinant Human Immunoglobulin alpha Fc receptor (FCAR), partial | Yeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli |
| CSB-CF008531HU | Recombinant Human Immunoglobulin alpha Fc receptor (FCAR) | in vitro E.coli expression system |
